Community Clinical Oncology Program

Investigators:

Andrew D. Jacobs, M.D., Unit Medical Director
David M. Aboulafia, M.D., Hematology/Oncology
K. Ray Badiozamani, M.D., Radiation Oncology
R. Alex Hsi, M.D., Radiation Oncology
Andrew D. Jacobs, M.D., Hematology/Oncology
Berit L. Madsen, M.D., Radiation Oncology
Thomas W. Malpass, M.D., Hematology/Oncology
Mary Pender-Schenck, M.D., Hematology/Oncology
Henry O. Otero, M.D., Hematology/Oncology
Vincent J. Picozzi, Jr., M.D., Hematology/Oncology
Huong T. Pham, M.D., Radiation Oncology
Guobin Song, M.D., Ph.D., Radiation Oncology
Lynne P. Taylor, M.D., Neurology
Jacqueline Vuky, M.D., Hematology/Oncology

The Virginia Mason Community Clinical Oncology Program (CCOP) is funded through a National Cancer Institute (NCI) grant and was one of the first to be established in the United States, demonstrating Virginia Mason's long standing commitment to clinical research. VM's CCOP, created in l983, works closely with the oncology providers at Virginia Mason as well as oncologists throughout Washington, Idaho and Alaska, a total of 36 providers at four sites across the Pacific Northwest.

NCI has selected approximately 60 major research centers as grant recipients for CCOP nationwide. The program is a comprehensive way to disseminate the latest cancer prevention and treatment research findings to the community. Established in l983 by NCI, CCOP enables patients and physicians to participate in clinical trials in 34 states across the country, the District of Columbia and Puerto Rico.

VM's CCOP provides patients with access to a variety of clinical research trials such as national chemotherapy prevention trials, cancer treatment trials and quality of life/symptom management trials. The symptom management trials now include some scientific study of complementary medicine (agents such as ginger, St. John's Wort, soy and coenzyme Q10) in controlling side effects and symptoms often experienced by patients. Currently, the CCOP has 29 studies open for enrollment.